The changing paradigm of managing Merkel cell carcinoma in Australia: An expert commentary.
Merkel cell carcinoma
clinical trials
immunotherapy
management
radiotherapy
Journal
Asia-Pacific journal of clinical oncology
ISSN: 1743-7563
Titre abrégé: Asia Pac J Clin Oncol
Pays: Australia
ID NLM: 101241430
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
03
01
2020
accepted:
30
05
2020
pubmed:
7
8
2020
medline:
6
1
2021
entrez:
7
8
2020
Statut:
ppublish
Résumé
Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine tumor of the skin with an estimated disease-associated mortality of 15-33%. Australia has a higher incidence of MCC compared to the rest of the world, thought to be due to a higher ultraviolet index. The Australian MCC population is distinct from the MCC population of the Northern hemisphere, characterized by a predominantly viral negative etiology with high tumor mutational burden. The optimal management of MCC and the choice of treatment modality vary significantly across the world and even between institutions within Australia. Historically, the treatment for MCC has been resection followed by radiotherapy (RT), though definitive RT is an alternative treatment used commonly in Australia. The arrival of immune checkpoint inhibitors and the mounting evidence that MCC is a highly immunogenic disease is transforming the treatment landscape for MCC. Australia is playing a key role in the further development of treatment options for MCC with two upcoming Australian/New Zealand investigator-initiated clinical trials that will explore the interplay of RT and immunotherapy in the treatment of early and late stage MCC.
Identifiants
pubmed: 32757453
doi: 10.1111/ajco.13407
pmc: PMC7754344
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
312-319Subventions
Organisme : Merck Serono
Informations de copyright
© 2020 The Authors. Asia-Pacific Journal of Clinical Oncology published by John Wiley & Sons Australia, Ltd.
Références
Front Pharmacol. 2018 Mar 05;9:185
pubmed: 29556198
Ann Surg Oncol. 2020 Jun;27(6):1978-1985
pubmed: 32103415
Head Neck. 2018 Dec;40(12):2704-2713
pubmed: 29934958
J Am Acad Dermatol. 2013 Mar;68(3):425-32
pubmed: 23200197
Science. 2008 Feb 22;319(5866):1096-100
pubmed: 18202256
J Invest Dermatol. 2017 Apr;137(4):819-827
pubmed: 27815175
Pathology. 2014 Apr;46(3):205-10
pubmed: 24614722
Australas J Dermatol. 2015 Feb;56(1):19-24
pubmed: 25369110
Ann Oncol. 2012 Apr;23(4):1074-80
pubmed: 21750118
Br J Dermatol. 2016 Feb;174(2):273-81
pubmed: 26480031
J Cutan Pathol. 2012 Oct;39(10):911-7
pubmed: 22882157
Hum Pathol. 2011 Oct;42(10):1385-90
pubmed: 21453956
JAMA Oncol. 2018 Sep 1;4(9):e180077
pubmed: 29566106
Clin Oncol (R Coll Radiol). 2012 Nov;24(9):e131-6
pubmed: 22626522
Cancer. 2017 Apr 15;123(8):1464-1474
pubmed: 27925665
J Immunother Cancer. 2018 Mar 23;6(1):23
pubmed: 29566749
J Clin Oncol. 2019 Mar 20;37(9):693-702
pubmed: 30726175
Am J Pathol. 1992 Feb;140(2):427-47
pubmed: 1371204
Curr Probl Cancer. 2010 Jan-Feb;34(1):14-37
pubmed: 20371072
J Cutan Med Surg. 2000 Oct;4(4):186-95
pubmed: 11231196
Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1430-5
pubmed: 20708847
J Invest Dermatol. 2011 Aug;131(8):1631-8
pubmed: 21562568
Cancer Med. 2016 Sep;5(9):2294-301
pubmed: 27431483
J Surg Oncol. 2005 Jan 1;89(1):1-4
pubmed: 15611998
Head Neck. 2016 Apr;38 Suppl 1:E452-8
pubmed: 25645649
J Am Acad Dermatol. 2018 Mar;78(3):457-463.e2
pubmed: 29102486
Int J Oral Maxillofac Surg. 2010 Nov;39(11):1086-90
pubmed: 20678899
Lancet Oncol. 2016 Oct;17(10):1374-1385
pubmed: 27592805
Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):703-9
pubmed: 19939581
Asia Pac J Clin Oncol. 2020 Dec;16(6):312-319
pubmed: 32757453
JAMA Otolaryngol Head Neck Surg. 2015 Feb;141(2):137-41
pubmed: 25474617
J Clin Oncol. 2007 Mar 20;25(9):1043-7
pubmed: 17369567
Cancer Res. 2015 Dec 15;75(24):5228-34
pubmed: 26627015
Nat Rev Dis Primers. 2017 Oct 26;3:17077
pubmed: 29072302
Cancer Res. 2015 Sep 15;75(18):3720-3727
pubmed: 26238782
Future Oncol. 2017 Jun;13(14):1263-1279
pubmed: 28350180
Oncotarget. 2016 Jan 19;7(3):3403-15
pubmed: 26655088
Eur Arch Otorhinolaryngol. 2015 Feb;272(2):425-9
pubmed: 24633244
Ann Surg Oncol. 2014 Oct;21(11):3401-5
pubmed: 25001091
Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1401-7
pubmed: 7635780
N Engl J Med. 2016 Jun 30;374(26):2542-52
pubmed: 27093365
Radiat Oncol. 2012 Oct 17;7:171
pubmed: 23075308
Neuroendocrinology. 2015;101(3):223-35
pubmed: 25765179
Clin Radiol. 1989 Jan;40(1):85-7
pubmed: 2920525
J Am Acad Dermatol. 2012 Sep;67(3):395-9
pubmed: 22030017
Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732):
pubmed: 28893943
J Am Acad Dermatol. 2011 Nov;65(5):983-90
pubmed: 21641081
Am Surg. 2015 Aug;81(8):802-6
pubmed: 26215243
Oncogene. 2018 Mar;37(11):1409-1416
pubmed: 29321666
JAMA Dermatol. 2016 Sep 1;152(9):1001-7
pubmed: 27248515
Ann Surg Oncol. 2016 Oct;23(11):3564-3571
pubmed: 27198511
Nat Rev Clin Oncol. 2018 Dec;15(12):763-776
pubmed: 30287935
J Invest Dermatol. 2017 Jan;137(1):197-206
pubmed: 27592799
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e583-91
pubmed: 21775069
Australas Radiol. 2004 Sep;48(3):371-5
pubmed: 15344989
Ann Surg. 2011 Sep;254(3):465-73; discussion 473-5
pubmed: 21865945
Arch Dermatol. 2006 Jun;142(6):693-700
pubmed: 16785371
Future Oncol. 2017 Aug;13(19):1699-1710
pubmed: 28605939
Arch Otolaryngol Head Neck Surg. 2001 Feb;127(2):149-54
pubmed: 11177031
J Clin Oncol. 2005 Apr 1;23(10):2300-9
pubmed: 15800320
Head Neck. 2007 Mar;29(3):249-57
pubmed: 17163472
J Natl Cancer Inst. 2009 Jul 1;101(13):938-45
pubmed: 19535775
Ann Surg Oncol. 2016 Feb;23(2):573-8
pubmed: 26286197
Cancer Med. 2015 Aug;4(8):1161-70
pubmed: 25908228
J Natl Compr Canc Netw. 2018 Jun;16(6):742-774
pubmed: 29891526
Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):114-9
pubmed: 16125873
Am J Surg. 2018 Mar;215(3):384-387
pubmed: 29157891
J Clin Oncol. 2003 Dec 1;21(23):4371-6
pubmed: 14645427
Australas J Dermatol. 2009 Nov;50(4):249-56
pubmed: 19916967